About Us
About Us
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.
We believe that the areas of hepatitis C and oncology are two disease areas wherein significant unmet medical needs persist. Our objective is to develop new medicines that will improve the treatment outcomes for patients with these serious diseases.
Anadys’ expertise has been based on two distinct scientific approaches to treating disease. With ANA598, we are focused on developing a direct acting antiviral, interacting with and blocking the function of a component of the virus. With ANA773, we are stimulating the patient’s own immune system to attack either cancer cells or the hepatitis C virus by activating a key receptor on immune cells knows as TLR7. Our knowledge of TLR7 is supported by an extensive preclinical program exploring the pharmacology of this receptor and by previous clinical experience with other molecules that act by the TLR7 mechanism. We are leveraging this experience in an effort to more efficiently develop ANA773.
Both ANA598 and ANA773 are wholly owned by Anadys and reflect the Company’s expertise with direct antivirals and the TLR7 mechanism.
Read about our expertise in:
